Genta Inc. (GETA.OB) Cancer Drug Shown Effective with Chemotherapy in Advanced Melanoma
QualityStocks (November 20th, 2009) Writes:
Genta Inc. released the results from a pilot study on advanced melanoma incorporating the Company’s cancer drug Genasense(R) (oblimersen sodium). This study was featured earlier this week in a presentation at the World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin, Germany, an international conference organized every year by a co-leader of the AGENDA trial, the European Association of Dermatologic Oncology (EADO).
Genasense, delivered for the first time in a high-dose, 1-hour intravenous (IV) format, was used along with the most common melanoma drug temozolomide (Temodar(R); Schering Plough, Inc.), and a paclitaxel suspension (Abraxane(R); Abraxis Bioscience, Inc.). Using a standard dose and schedule of Genasense, 500 mg over 24 hours for 7 days, showed good tolerability for 18 patients and was associated with clinical activity in prior results using this investigational combination of drugs.
Genasense, administered in this more aggressive schedule (1-hour IV twice a week for 4 weeks at 900 mg
...Abraxane, Abraxis BioScience Inc., Berlin, Biopharmaceutical, cancer, chemical profile, Chemotherapy, co-leader, DNA/RNA, European Association of Dermatologic Oncology, Genasense, Genta Inc.;, Germany, GETA, Investing Lessons, Loretta M. Itri, Melanoma, neutropenia;, preliminary disease, president, Schering Plough Inc., Small & Micro Cap, stable disease, Temodar;


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)






